Drug – bio-affecting and body treating compositions – Immunoglobulin – antiserum – antibody – or antibody fragment,... – Derived from – or present in – food product
Reexamination Certificate
2001-07-13
2004-09-28
Kim, Vickie (Department: 1614)
Drug, bio-affecting and body treating compositions
Immunoglobulin, antiserum, antibody, or antibody fragment,...
Derived from, or present in, food product
C514S339000, C514S371000
Reexamination Certificate
active
06797268
ABSTRACT:
TECHNICAL FIELD
The present invention relates to an inhibitor of
Helicobacter pylori
adhesion and pharmaceutical compositions for oral administration useful for the effective prevention or treatment of peptic ulcers caused by
Helicobacter pylori.
BACKGROUND OF THE INVENTION
At present it is believed that eradication of
H. pylori
from the stomach is essential for completely treating peptic ulcers. The combination of an antibiotic and an inhibitor of gastric acid secretion has been generally proposed as a therapy for eradication of
H. pylori
as described below.
H. pylori
is a gram-negative spiral rod-shaped bacterium having flagella at one end and colonizing the human gastric mucosa. B. J. Marshall and J. R. Warren in Australia reported in 1983 that this bacterium was frequently detected in stomach biopsy specimens from patients with gastritis or gastric ulcers.
Since then, many reports have been published based on epidemiological studies, indicating that this bacterium causes gastritis, gastric ulcers, and duodenal ulcers and is associated with diseases such as gastric cancer. Once
H. pylori
colonizes gastric mucosa, it survives and persists in the stomach and cannot be eradicated, although the immune response to infection by
H. pylori
is strong, i.e., the antibody titer is high. Therefore, unless
H. pylori
is completely eliminated from the stomach by antibiotic therapy, the infection will return to the same level as before treatment within about a month after the administration of antibiotics is stopped. Additionally, the pH of the stomach is maintained very low by HCl, which is a strong acid, and therefore most antibiotics tend to be inactivated. For this reason, the combination of an antibiotic and a proton pump inhibitor which strongly suppresses the secretion of gastric acid is utilized for eradication of
H. pylori
. However, the administration of antibiotics for a long time has the serious problems of increasing antibiotic-resistant strains as well as causing side effects.
An immunological therapy approach using an oral vaccine has been proposed in order to solve problems such as side effects and the increase of antibiotic-resistant strains caused by treatment with antibiotics for the eradication of the bacteria. However, this approach has not been put to practical use. Also, an oral vaccine has problems with respect to the safety of adjutants in its practical application to humans. Additionally, the vaccine is predominantly used for prevention, and therefore it has no effect on patients who have already been infected with
H. pylori.
As an alternative immunotherapy, the use of egg antibodies against
H. pylori
whole cell has been proposed by Aiba et al. (The Meeting of the 30th Japan Germ-free Animal Gnotobiology Society, Program and Abstracts, p22, Requested Title 18, New Attempt for Inhibiting Helicobacter pylori, January 1997), and in Japanese Patent Application Kokai No. 4-275232 and transactions of Japan Agricultural Chemistry Society, 71, p52, 20p22 (1997). However, the antibodies against
H. pylori
whole cells cannot completely eliminate
H. pylori
from the stomach, and therefore do not provide a pharmaceutical composition effective for the prevention or treatment of peptic ulcers.
SUMMARY OF THE INVENTION
It is an object of the present invention to provide a pharmaceutical composition for use in preventing or treating diseases caused by
H. pylori
such as peptic ulcers, the composition being effective and safe without the disadvantages of side effects and an increase in drug-resistant strains which are associated with the use of antibiotics.
Other objects and advantages as well as the nature of the present invention will be apparent from the following description.
Previously the present inventors obtained information with respect to
H. pylori
adhesion in the gastric mucosa, which is the key to growth thereof in the stomach, which has strong acidity, and we provided specific antibodies against
H. pylori
urease from eggs for use in completely inhibiting colonization of
H. pylori
in the gastric mucosa (Japanese Patent Application Kokai No. 10-287585). Namely, the inventors found that
H. pylori
urease participates in the colonization of
H. pylori
in gastric mucosa, and in particular that
H. pylori
urease is an adhesin, and demonstrated that antibodies against
H. pylori
urease from chicken eggs are effective for inhibiting the
H. pylori
adhesion in the gastric mucosa by binding to urease as an adhesin of
H. pylori.
The present invention is an improvement on the above-mentioned invention, and it was made based on the discovery that the combination of the above-mentioned antibodies against
H. pylori
urease and an inhibitor of gastric acid secretion has a synergistic effect which enables a decreased dosage of the antibodies used for complete elimination of
H. pylori
from the stomach.
In one aspect, the present invention provides an inhibitor composition of
H. pylori
adhesion in the gastrointestinal tract of a mammal including humans, comprising (1) IgY antibodies obtained from at least one chicken egg laid by a hen which has been immunized with an antigenically effective amount of an isolated
Helicobacter pylori
urease, wherein said IgY antibodies are capable of specifically binding to
Helicobacter pylori
urease in the gastrointestinal tract of the mammal, and (2) an inhibitor of gastric acid secretion.
In another aspect, the present invention provides a pharmaceutical composition for preventing and/or treating a disease caused by or associated with
Helicobacter pylori
in a mammal including humans, comprising a pharmaceutically effective amount of the inhibitor composition comprising (1) IgY antibodies obtained from at least one chicken egg laid by a hen which has been immunized with an antigenically effective amount of an isolated
Helicobacter pylori
urease, wherein said IgY antibodies are capable of specifically binding to
Helicobacter pylori
urease in the gastrointestinal tract of the mammal, and (2) an inhibitor of gastric acid secretion, and a pharmaceutically acceptable carrier or diluent.
REFERENCES:
patent: 6419926 (2002-07-01), Kodama et al.
patent: 0 877 032 (1998-11-01), None
patent: 1 010 434 (2000-06-01), None
patent: 04-275232 (1992-09-01), None
patent: 10-287585 (1998-10-01), None
patent: 2001-081049 (2001-03-01), None
Tagagi et al., Plaunotol Suppresses interleukin-8 secretion . . . , abstract, Journal o fGastroenterology and Hepatology, 2000, 15(4), 374-380.*
Romano et al., Effect of cimetidine and ranitidine on drug induced . . . , abstract, Gut. 1989, vol. 30(10), pp. 1313-1322.*
Aiba et al, “New Attempt for InhibitingHelicobactor pylori”, The Meeting of the 30thJapan Germ-free Animal Gnotobiology Society, Program and Abstracts (Jan., 1997) p. 22, abstract 18, with attached English language translation.
Tani et al., “Effects of anti-Helicobactor pyloriantibodies from egg yolk antibodies onHelicobacter pylor”, Transactions of Japan Agricultural Society (Mar., 1997) p. 52, vol. 71, abstract 20 p. 22, with attached English language translation.
Shimizu et al. “Molecular Stability of Chicken and Rabbit Immunoglobulin G,”Bioscience Biotechnology and Biochemistry, 1992, pp. 270-274, vol. 56, No. 2, Japan Society for Bioscience, Biotechnology and Agrochemistry, Japan.
Kimura Nobutake
Kodama Yoshikatsu
Burns Doane , Swecker, Mathis LLP
Ghen Corporation
Kim Vickie
LandOfFree
Pharmaceutical composition useful in the treatment of peptic... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Pharmaceutical composition useful in the treatment of peptic..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Pharmaceutical composition useful in the treatment of peptic... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3263569